Introducing Spermosens
Spermosens develops revolutionizing medical device products for male infertility for personalized assisted reproduction.
WHO estimates that globally more than 48 million couples are affected by infertility. Unfortunately, less than 1 out of 5 Fertility treatments succeed. Historically the male factor has not been looked upon as much even though it contributes equally as the female factor. Spermosens is developing products based on a patent-protected technology for male infertility diagnostics and infertility treatment.
With Spermosens’ first product it will, for the first time, be possible to determine sperms’ ability to bind to the egg cell. By using JUNO-Checked early in the process additional information is generated. This is expected to improve decision making between different treatments, ultimately leading to better results.
- Fewer IVF treatments to fertilisation
- Shorter waiting time for treatment
- Improved quality of life
- Competitive advantage for clinics
- Reduced costs
“Spermosens’ goal is to improve male fertility diagnostics and treatment through the introduction of ground-breaking products. Spermosens’ first patented product JUNO-Checked measures the binding capacity between sperm and egg cell, which is a prerequisite for natural fertilization. The results are deemed to help clinicians choose the appropriate treatment method. Ultimately leading to better results.”
Ulrik Nilsson, CFO
Sources
- WHO, 2020. Infertility, World Health Organization.
https://www.who.int/news-room/fact-sheets/detail/infertility
